BEI RESOURCE DEPOSIT FORM FOR - BEI Resources

DEPOSIT FORM – Part 2 of 2 

ANTIBODIES, HYBRIDOMAS & ANTISERA 

INFORMATION REQUIRED FOR DEPOSIT 

INSTRUCTIONS TO DEPOSITOR: Please fill in the relevant and available information about each deposit, and return 

electronically to the collection scientist, or fax to 703-365-2725, prior to shipping the Material. Two printed and 

signed originals of part 1 of 2 must also be sent prior to the shipment. Additional information, references or pages 

may be attached as needed. This information helps us better characterize and preserve the Materials. 

The “MATERIAL” subject to this Deposit Form is: 

Name of Antibody/antiserum/hybridoma:________________________________________________________ 

1. BACKGROUND INFORMATION: 

a. Name of investigator who developed the material & name of investigator’s institution: 

_____________________________________________________________________________________ 

b. Reason you feel this antibody is important: ____________________________________________________ 

_____________________________________________________________________________________ 

c. References: Original description or other appropriate publications. Please enclose a copy of relevant 

references. ___________________________________________________________________________ 

_____________________________________________________________________________________ 

d. Antigen: _______________________________________________________________________________ 

1. Was the antigen derived from a human Yes □ No □ 

If yes, were the IRB approved consent form(s) obtained 

Yes □ No □ 

If yes again, please provide RPN Number:_________________________ 

e. Antigen characteristics: intact cell □ crude extract □ purified protein □ cell lysate □ 

purified recombinant preparation □ synthetically prepared □ 

conjugated to: 

______________________________________________________________________ 

Adjuvant: ____________________________________________________________________________ 

f. Source of antibody/antiserum/hybridoma: ______________________________________________________ 

Biodefense and Emerging Infections Research Resources Repository 800-359-7370 

P.O. Box 4137 Fax: 703-365-2898 

Manassas, VA 20108-4137 USA 

E-mail: contact@beiresources.org 

www.beiresources.org Effective Date: 09/04/2007 

Revision: 1 

© 2004 American Type Culture Collection (ATCC). All rights reserved. Document ID: 4388 

Page 5 of 10



Age of immunized subject:______________________________________________________________ 

Route of immunization ( footpad, intrascapular, intrperitoneal, etc.): ______________________________ 

Adjuvant: ____________________________________________________________________________ 

Was antigen conjugated 

Yes □ No □ 

If yes, name conjugate (e.g., BSA, ovlabumin, etc.): ________________________________________ 

g. Screening Assay_________________________________________________________________________ 

______________________________________________________________________________________ 

2. ANTIBODIES (monoclonal): 

a. Was the antibody obtained from a human Yes □ No □ 

If yes, were the IRB approved consent form(s) obtained Yes □ No □ 

If yes again, please provide RPN Number: __________________________________________________ 

b. Has the antibody been purified: Yes □ No □ Unknown □ 

If yes, state method: ___________________________________________________________________ 

c. Is antibody conjugated Yes □ No □ 

If yes, name conjugate (e.g., fluorescein, rhodamine, alkaline phosphatase, etc.): 

____________________________________________________________________________________ 

d. Antibody: 

Specificity: ___________________________________________________________________________ 

Cross-reactivity (if any):_________________________________________________________________ 

Ig Class: __________________________________ Subclass: _________________________________ 

Light chain: lambda □ kappa □ Unknown □ 

e. Special properties, characteristics, or use: 

Can it be used for: 

Western blots Yes □ No □ Unknown □ 

Immunoprecipitation Yes □ No □ Unknown □ 

Flow cytometry Yes □ No □ Unknown □ 


P.O. Box 4137 Fax: 703-365-2898 




Revision: 1 


Page 6 of 10



Immunocytochemistry Yes □ No □ Unknown □ 

Is it neutralizing Yes □ No □ Unknown □ 

Can it bind to both denatured and native protein Yes □ No □ Unknown □ 

Can it be labeled or radio-labeled without loosing specificity Yes □ No □ Unknown □ 

f. Recommended titers for use in: 

Western blots: __________________________ 

Radioimmunoassays: _________________________ 

Immunoprecipitation: _____________________ 

Elisa: _____________________________________ 

Flow cytometry: _________________________ 

Neutralization assays: ________________________ 

Immunohistochemistry: _______________ 

3. HYBRIDOMAS: 

a. Brief history since origin (important changes in culture conditions or methods, clonal method, if any, whether 

antibiotics have been used, current passage number, population doublings (PDLs), etc.): 

_____________________________________________________________________________________ 

_____________________________________________________________________________________ 

b. Was the hybridoma obtained from a human Yes □ No □ 

If yes, were the IRB approved consent form(s) obtained Yes □ No □ 

If yes again, please provide RPN Number: __________________________________________________ 

c. Hybridoma origin 

Species of antibody producing cell: _______________________________________________________ 

Was immunization conducted in vivo or in vitro _____________________________________________ 

Fusion partner (designation/strain/species): _________________________________________________ 

d. Antibody: 

Specificity: ___________________________________________________________________________ 


Ig Class: _______________________________________ Subclass: ____________________________ 



P.O. Box 4137 Fax: 703-365-2898 




Revision: 1 


Page 7 of 10



e. Medium, antibiotics, etc. used in stock transferred to BEI Resources:________________________________ 

________________________________________________________________________________________ 

f. Recommended culture medium and subculture procedure: ________________________________________ 

______________________________________________________________________________________ 

g. Recommendations for freezing cells, if any: ____________________________________________________ 

4. ANTISERUM: 

a. Dates of immunization protocol (was antibody from a primary response, secondary, etc.): 

_____________________________________________________________________________________ 

b. Was antisera pooled Yes □ No □ Unknown □ 

If yes, how many subjects contributed to pool ______________________________________________ 

c. Has the antibody been purified: Yes □ No □ Unknown □ 

If yes, state method: ___________________________________________________________________ 

d. Is antibody in serum conjugated Yes □ No □ 

If yes, name conjugate (e.g., fluorescein, rhodamine, alkaline phosphatase, etc.): 

____________________________________________________________________________________ 

e. Antibody: 

Specificity: ___________________________________________________________________________ 


Ig Class: __________________________________ Subclass: _________________________________ 


f. Special properties, characteristics, or use: 

Can it be used for: 

Western blots Yes □ No □ Unknown □ 

Immunoprecipitation Yes □ No □ Unknown □ 

Flow cytometry Yes □ No □ Unknown □ 

Immunocytochemistry Yes □ No □ Unknown □ 

Is it neutralizing Yes □ No □ Unknown □ 

Can it bind denatured as well as native protein Yes □ No □ Unknown □ 

Can it be labeled or radiolabeled without loosing specificity Yes □ No □ Unknown □ 


P.O. Box 4137 Fax: 703-365-2898 




Revision: 1 


Page 8 of 10



g. Recommended titers for use in: 

Western blots: _____________________________ Neutralization assays: _________________________ 

Immunoprecipitation: ________________________ Radioimmuassays: ___________________________ 

Flow cytometry: ____________________________ Elisa: _____________________________________ 

Immunohistochemistry: ______________________ 

5. FINAL PREPARATION OF MATERIAL AS SUBMITTED TO BEI/ATCC 

a. Has the Material been tested for mycoplasma contamination: Yes □ No □ 

If yes, indicate methods and results: ______________________________________________________ 

___________________________________________________________________________________ 

b. Identify any reagents of plant/animal origin used in production of this Material (i.e., serum growth factors, 

trypsin, etc.) and the manufacturer and country of origin: ______________________________________ 

____________________________________________________________________________________ 

____________________________________________________________________________________ 

c. Describe any other Quality Control tests (biochemical or molecular) and results: ____________________ 

____________________________________________________________________________________ 

d. Number of vials being transferred to BEI Resources: __________________________________________ 

e. Titer/concentration per vial: _____________________________________________________________ 

f. Type of vial in which antibody will be provided: 

____________________________________________________________________________________ 

g. Label designation on vials being transferred to BEI Resources: 

________________________________________________ 

6. PRESERVATION/SHIPPING CONDITIONS 

a. Recommended storage conditions (temp., etc.) __________________________________________________ 


P.O. Box 4137 Fax: 703-365-2898 




Revision: 1 


Page 9 of 10



b. Recommended shipping conditions: ________________________________________________________ 

____________________________________________________________________________________ 

c. Special handling conditions required: ________________________________________________________ 

_____________________________________________________________________________________ 

7. SAFETY AND REGULATORY INFORMATION 

a. Does this antibody preparation contain material hazardous to: Humans______ Animals ______ Plants 

If so, what is the Biosafety Level (BSL) required to handle it (refer to Biosafety in Microbiological and Biomedical 

Laboratories, 4 th ed. HHS Publications No. (CDC) 93-8395 U.S. Department of Health and Human Services. The complete text is available 

atww.cdc.gov/od/ohs/biosfty/bmbl4toc.htm): 

__________________________________________________________________________________ 

b. Has the Material been screened for the presence of contaminating pathogens If 

Yes, please specify test and results: ________________________________________ 

c. Is the Material in solution Yes □ No □ 

d. Does the Material require special permits Yes □ No □ 

If yes, please specify: _________________________________________________________________ 

e. Is this antibody specific for a material listed on the U.S. Government’s Select Agent list Yes □ No □ 

f. List any routine vaccines or surveillance provided to investigators handling this Agent. 

________________________________________________________________________________________ 

g. Is the Material radioactive Yes □ No □ 

If yes, specify isotope, chemical composition, total radioactivity per vial and date radioactivity was measured. 

_________________________________________________________________________________________ 

_________________________________________________________________________________________ 


P.O. Box 4137 Fax: 703-365-2898 




Revision: 1 


Page 10 of 10

BEI RESOURCE DEPOSIT FORM FOR - BEI Resources

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?